Chen W Q, Dai X N, Yu Y, Wang Q, Liang J Y, Ke Y N, Yi C H, Lin J
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Oct 18;52(5):886-891. doi: 10.19723/j.issn.1671-167X.2020.05.015.
To analyze the clinical features and prognosis in patients with primary Sjögren's syndrome (pSS) and autoimmune liver diseases (ALD).
A retrospective analysis of clinical manifestation and prognosis was performed in patients with ALD or without ALD during the three years (February 2014 to December 2017).
Totally, 203 patients with pSS were included in this study, 68 patients had ALD (31 patients with autoimmune hepatitis, 37 patients with primary biliary cholangitis), while 135 patients did not have ALD. There were no differences between the two groups regarding age, gender, clinical manifestations, such as dry mouth, dry eyes, pain, fatigue, lymphadenopathy, glandular swelling, cutaneous involvement, lung involvement, and renal involvement, and the incidence rate of other autoimmune diseases, such as autoimmune thyroid disease, rheumatoid arthritis, and vasculitis. There were also no differences in the titer of antinuclear antibody (ANA), the positive rates of anti-Sjögren's syndrome A antibody (SSA), SSA52, and anti-Sjögren's syndrome B antibody (SSB), and at the levels of erythrocyte sedimentation rate and C-reactive protein between the two groups. Most importantly, the pSS patients with ALD had a shorter disease course, a higher positive rate of anti-mitochondrial M2 antibody (AMA-M2) and anti-centromere antibody, a higher level of IgG and IgM, a lower level of complement 3, and a decreased number of blood cells. They also had a higher level of liver related serum index, such as alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase and total bilirubin, direct bilirubin, indirect bilirubin, a higher incidence rate of liver cirrhosis, an increased death incident (the mortality was 13.24% in the pSS patients with ALD, while 2.96% in the controls, =0.013), and a worse prognosis. Binary Logistic regression analysis revealed that liver cirrhosis, the EULAR Sjögren's syndrome disease activity index (ESSDAI) scores and the level of total bilirubin were the prognostic factors of mortality in the pSS patients with ALD. The survival curve was estimated by the Kaplan-Meier method. It demonstrated that the pSS patients with ALD had a lower survival rate when compared with the controls.
The patients with both pSS and ALD will suffer from a more severe disease and a higher death incident. We should pay more attention to these patients and provide a better symptomatic treatment for them during clinical practice.
分析原发性干燥综合征(pSS)合并自身免疫性肝病(ALD)患者的临床特征及预后。
对2014年2月至2017年12月期间患或未患ALD的患者进行临床表现及预后的回顾性分析。
本研究共纳入203例pSS患者,其中68例合并ALD(自身免疫性肝炎31例,原发性胆汁性胆管炎37例),135例未合并ALD。两组在年龄、性别、临床表现(如口干、眼干、疼痛、疲劳、淋巴结病、腺体肿大、皮肤受累、肺部受累及肾脏受累)以及其他自身免疫性疾病(如自身免疫性甲状腺疾病、类风湿关节炎及血管炎)的发病率方面无差异。两组在抗核抗体(ANA)滴度、抗干燥综合征A抗体(SSA)、SSA52及抗干燥综合征B抗体(SSB)阳性率以及红细胞沉降率和C反应蛋白水平方面也无差异。最重要的是,合并ALD的pSS患者病程较短,抗线粒体M2抗体(AMA-M2)及抗着丝点抗体阳性率较高,IgG和IgM水平较高,补体3水平较低,血细胞数量减少。他们的肝脏相关血清指标水平也较高,如丙氨酸氨基转移酶、天冬氨酸氨基转移酶、γ-谷氨酰转移酶、碱性磷酸酶以及总胆红素、直接胆红素、间接胆红素,肝硬化发病率较高,死亡事件增加(合并ALD的pSS患者死亡率为13.24%,而对照组为2.96%,P=0.013),预后较差。二元Logistic回归分析显示,肝硬化、欧洲抗风湿病联盟干燥综合征疾病活动指数(ESSDAI)评分及总胆红素水平是合并ALD的pSS患者死亡的预后因素。采用Kaplan-Meier法估计生存曲线。结果表明,合并ALD的pSS患者生存率低于对照组。
pSS合并ALD的患者病情更严重,死亡事件发生率更高。临床实践中应更加关注这些患者并为其提供更好的对症治疗。